The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVRG.L Regulatory News (DVRG)

  • There is currently no data for DVRG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Completion of Compulsory Acquisition; TVR

15 Jan 2021 07:00

RNS Number : 7734L
Deepverge PLC
15 January 2021
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. IN PARTICULAR, THIS ANNOUNCEMENT SHOULD NOT BE RELEASED, PUBLISHED, DISTRIBUTED, FORWARDED OR TRANSMITTED, IN WHOLE OR IN PART, IN, INTO OR FROM ANY RESTRICTED JURISDICTION, INCLUDING THE US.

15 JANUARY 2021

RECOMMENDED ALL SHARE OFFER

for

MODERN WATER PLC

by

DEEPVERGE PLC

COMPLETION OF COMPULSORY ACQUISITION

On 28 August 2020 the board of directors of DeepVerge PLC (DeepVerge) and the Independent Directors of Modern Water PLC (Modern Water) announced that they had reached agreement on the terms of a recommended all share offer to be made by DeepVerge for the entire issued and to be issued share capital of Modern Water (the Offer). The full terms and conditions of the Offer and the procedures for acceptance were set out in the offer document published by DeepVerge on 13 October 2020 (the Offer Document).

As at 1.00 p.m. on 17 November 2020, the closing date of the Offer, DeepVerge had received valid acceptances from shareholders of Modern Water in respect of a total of 520,323,686 Modern Water Shares, representing approximately 93.47% of the issued share capital of Modern Water.

Compulsory acquisition

Further to DeepVerge's announcement on 17 November 2020 that it had received valid acceptances in respect of more than 90% in nominal value of the Modern Water Shares to which the Offer relates, the Company commenced compulsory acquisition proceedings under sections 974-991 of the Companies Act 2006. The Company announces that the compulsory acquisition of all remaining Modern Water Shares has now completed.

Share allotment

The Company has today allotted 3,636,915 New DeepVerge Shares in respect of the Modern Water Shares compulsorily acquired, and application will be made for these shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur at 8.00 a.m. on 20 January 2021.

Total Voting Rights

The Company's total issued share capital, following the issue of the new Ordinary Shares, will be 169,514,211 ordinary shares of 0.1 pence per share. As the Company does not hold any shares in Treasury, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company following Admission.

 

Enquiries

DeepVerge plc

Ross Andrews, Chairman

Contact via DeepVerge's PR

 

SPARK Advisory Partners Limited

(Nominated Adviser)

 

Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker/Zoe Alexander

+44 (0) 20 3657 0050

 

Mo PR (Financial PR adviser to DeepVerge)

 

 

Mo Noonan

 

+44 (0) 7876 444977

About DeepVerge plc (www.deepverge.com)

DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins. Utilising artificial intelligent data analytics to scientifically prove the impact of skincare product claims on skin microbiome for most of the top 20 global cosmetic company clients and remotely detect and identify in real-time, dangerous pathogens in wastewater treatment plants, drinking water, rivers, lakes and reservoirs.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEFLFFDLTISLIL
Date   Source Headline
30th Sep 20224:35 pmRNSPrice Monitoring Extension
30th Sep 202211:06 amRNSSecond Price Monitoring Extn
30th Sep 202211:00 amRNSPrice Monitoring Extension
22nd Sep 20227:00 amRNSInterim Results
13th Sep 20227:00 amRNSBlue Carbon Resilience project
5th Aug 20227:00 amRNSTrading Update
1st Aug 20227:00 amRNSModern Water secures £2.1m projects
20th Jul 20221:42 pmRNSResult of AGM
20th Jul 20227:00 amRNSDeepVerge to explore options for Labskin Division
19th Jul 20224:41 pmRNSSecond Price Monitoring Extn
19th Jul 20224:36 pmRNSPrice Monitoring Extension
18th Jul 20227:01 amRNSModern Water monitoring systems deal worth £1.4m
4th Jul 20227:00 amRNSSkin Trust Club - update
30th Jun 20227:00 amRNSModern Water Q2 orders exceed £3m, RPT
27th Jun 202211:50 amRNSNotice of AGM
23rd Jun 20227:12 amRNSFinal Results
13th Jun 20227:00 amRNSNotice of Final Results and Annual Report
1st Jun 20221:36 pmRNSSkin Trust Club wins Best New Disrupter Brand
30th May 20227:00 amRNSTesting Services Framework Ag with Abingdon Health
26th Apr 20227:00 amRNSDeepVerge presents at Global Group Investor Summit
19th Apr 20227:00 amRNSUpdate; Manuf'g Service Agreement with Microsaic
19th Apr 20227:00 amRNSHolding(s) in Company
29th Mar 20227:00 amRNSMoU with Abingdon Health for lateral flow tests
28th Mar 20227:00 amRNS1st UK Deployments of Microtox®PD in Wastewater
18th Mar 202211:05 amRNSSecond Price Monitoring Extn
18th Mar 202211:00 amRNSPrice Monitoring Extension
17th Mar 202210:59 amRNSDirector Dealing
17th Mar 20227:00 amRNSAcquisition; Loan Facility for global expansion
11th Mar 20229:05 amRNSSecond Price Monitoring Extn
11th Mar 20229:00 amRNSPrice Monitoring Extension
11th Mar 20227:00 amRNSDeepVerge Q1 production orders up 39% to £5m
21st Feb 20227:00 amRNS82% of Skin Trust Club members purchase via App
19th Jan 20227:00 amRNSMicrotoxPD detects 3 COVID variants of concern
17th Jan 202211:05 amRNSSecond Price Monitoring Extn
17th Jan 202211:00 amRNSPrice Monitoring Extension
11th Jan 20227:00 amRNSTrading Update
6th Jan 20227:00 amRNSMicrotox CTM installed ahead of Winter Olympics
13th Dec 20217:00 amRNSAmends to Agreement with Microsaic Systems; RPT
10th Dec 20219:00 amRNSPrice Monitoring Extension
10th Dec 20217:00 amRNSCompact Microtox® PD launch scheduled for Q1 2022
9th Dec 20214:41 pmRNSSecond Price Monitoring Extn
9th Dec 20214:36 pmRNSPrice Monitoring Extension
26th Nov 20217:00 amRNSRelated Party Transaction
11th Nov 20217:00 amRNSU.S. launch of Skin Trust Club at Beauty Connect
4th Nov 20218:00 amRNSPDMR Dealing
4th Nov 20217:00 amRNSGrant supports DeepVerge Centre of Excellence
3rd Nov 20217:00 amRNSConfirmation of Post-Offer Intention Statements
28th Oct 20217:00 amRNSMicrotox® PD installations as part of nat'l trial
21st Oct 20219:05 amRNSSecond Price Monitoring Extn
21st Oct 20219:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.